This trial was designed to assess the tolerability of different doses of abituzumab in combination with cetuximab and irinotecan ( phase I ) and explore the efficacy and tolerability of the combination versus that of cetuximab and irinotecan in patients with metastatic CRC ( mCRC ) ( phase II part ) .